Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchiectasis
Conditions
Bronchiectasis
Trial Timeline
Apr 30, 2014 → Oct 19, 2016
NCT ID
NCT02106832About Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo is a phase 3 stage product being developed by Novartis for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02106832. Target conditions include Bronchiectasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02106832 | Phase 3 | Completed |
Competing Products
20 competing products in Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| AZD9668 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD5069 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin DPI (BAYQ3939) + Placebo | Novartis | Phase 3 | 77 |
| Placebo to Ciprofloxacin DPI (BAYQ3939) | Novartis | Pre-clinical | 23 |
| QBW251 + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin (Cipro, BAYQ3939) + Placebo | Novartis | Phase 2 | 52 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Aztreonam lysine | Gilead Sciences | Approved | 84 |
| AZLI | Gilead Sciences | Phase 2 | 51 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Itepekimab (SAR440340) + Placebo | Sanofi | Phase 2 | 51 |
| CSL787 + Placebo | CSL | Phase 1 | 32 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Group A + Group B | Bayer | Pre-clinical | 20 |
| BAY85-8501 + Placebo | Bayer | Phase 2 | 49 |